Is ARWR a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Arrowhead Pharmaceuticals (ARWR) rests on REDEMPLO (plozasiran) launch and label expansion: Plozasiran is now approved for FCS in the U.S., China, Canada, Australia, and the EU, giving Arrowhead its first commercial product. The bear case rests on arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. Analysts covering it publish targets from $87.00 to $126.00 against a $86.29 price, so even the professionals disagree by 37% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Arrowhead Pharmaceuticals is a biopharmaceutical company built around RNA interference (RNAi), using its TRiM (Targeted RNAi Molecule) platform to design small interfering RNA (siRNA) medicines that silence disease-causing genes in the liver and, increasingly, in tissues like the lung and muscle. Its lead drug, plozasiran (marketed as REDEMPLO), targets APOC3 to lower triglycerides and was approved by the U.S. FDA in November 2025 for familial chylomicronemia syndrome (FCS), with additional approvals in China, Canada, Australia, and the European Union. Behind it sits a broad pipeline spanning cardiometabolic disease, obesity, pulmonary, CNS, and muscle targets, several of which are partnered. The investment picture is defined by large partnerships and lumpy, milestone-heavy revenue rather than steady product sales. A 2024-2025 global license and collaboration agreement with Sarepta Therapeutics brought roughly ~$825M in upfront value (about ~$500M cash plus ~$325M equity) and has since triggered nine-figure milestone payments, while Amgen (olpasiran for Lp(a)) and Novartis are additional partners. Those deals, plus capital raises, left Arrowhead with over ~$1.7B in cash resources as of early 2026, funding a long runway. Because much of the reported revenue is deal-driven, quarterly results swing sharply, and investors weigh the emerging REDEMPLO launch and late-stage readouts against continued operating losses in non-milestone quarters.
The bull case: what would have to be true for $126.00
The most optimistic published target on ARWR is $126.00, +46.0% from the $86.29 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. REDEMPLO (plozasiran) launch and label expansion
Plozasiran is now approved for FCS in the U.S., China, Canada, Australia, and the EU, giving Arrowhead its first commercial product. The larger commercial opportunity would come from broader indications like severe hypertriglyceridemia, where the addressable patient population is far bigger than the rare FCS setting.
2. Partnership economics
The Sarepta collaboration delivered roughly ~$825M in upfront value and has generated additional milestone payments (including ~$100M and ~$200M tranches reported in late 2025). Amgen's olpasiran and other partnered programs add royalty and milestone potential without Arrowhead bearing all the development cost, though the timing of these payments is uneven.
3. Broad RNAi pipeline beyond the liver
Arrowhead's TRiM platform extends siRNA delivery beyond hepatic targets toward lung, muscle, and CNS tissues, supporting candidates in cardiometabolic disease, obesity (such as ARO-INHBE), and pulmonary conditions. A deep, diversified pipeline gives multiple shots on goal but also spreads capital and clinical risk across many programs.
4. Strong balance sheet and runway
Following partner payments and equity offerings, Arrowhead reported total cash resources of roughly ~$1.78B in early 2026. That funding reduces near-term dilution pressure and lets the company advance late-stage trials and the REDEMPLO commercial build-out without immediate financing risk.
The bear case: what would have to be true for $87.00
The most pessimistic published target is $87.00, +0.8% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Arrowhead Pharmaceuticals is worth if the risks below bite instead of the drivers above.
Arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. The commercial uptake of REDEMPLO in the small FCS population is unproven, and broader label expansion depends on clinical and regulatory outcomes that can fail or slip. Competition in RNAi and lipid-lowering is intense from larger, better-capitalized rivals. Clinical trial setbacks, safety findings, regulatory delays, and partner decisions (including a partner pausing or returning a program) could all materially affect the stock, which is volatile like most clinical-stage biotech.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ARWR already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ARWR
11 analysts cover ARWR, with an average target of $104.27 (+20.8% against $86.29) and a split of 12 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ARWR forecast and price target page.
How is ARWR valued? (as of JULY 2026)
Snapshot for ARWR as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY2025, ended Sept 2025): ~$829M
- Q1 FY2026 revenue (Oct-Dec 2025): ~$264M
- Q2 FY2026 revenue (Jan-Mar 2026): ~$74M
- Total cash resources (early 2026): ~$1.78B
- Sarepta deal upfront value: ~$825M (~$500M cash + ~$325M equity)
- Profitability: Milestone quarters profitable; loss-making without milestones
Arrowhead's reported revenue is dominated by partnership and milestone payments, which makes results swing dramatically between quarters (a large Q1 FY2026 milestone quarter versus a much smaller Q2). Traditional valuation multiples are of limited use for a company at this stage, so investors tend to focus on the REDEMPLO launch trajectory, pipeline readouts, cash runway, and deal flow rather than trailing earnings.
How do you decide if ARWR is a buy?
Rather than asking whether ARWR is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ARWR indirectly through an index or sector ETF before adding more.
What would change your mind on ARWR
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: REDEMPLO (plozasiran) launch and label expansion stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ARWR stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ARWR against your real portfolio and see your actual exposure before deciding.
Investing in Arrowhead Pharmaceuticals with AI
Connect the broker you already use and ask Walnut's AI how ARWR fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is ARWR a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on REDEMPLO (plozasiran) launch and label expansion, with revenue (fy2025, ended sept 2025) at ~$829M. The bear case rests on arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. Analysts covering it are spread from $87.00 to $126.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ARWR?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $87.00, +0.8% from the $86.29 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for ARWR?
+
REDEMPLO (plozasiran) launch and label expansion. Plozasiran is now approved for FCS in the U.S., China, Canada, Australia, and the EU, giving Arrowhead its first commercial product. The most optimistic analyst target on ARWR is $126.00, +46.0% from the $86.29 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for ARWR?
+
Arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. The commercial uptake of REDEMPLO in the small FCS population is unproven, and broader label expansion depends on clinical and regulatory outcomes that can fail or slip. Competition in RNAi and lipid-lowering is intense from larger, better-capitalized rivals. Clinical trial setbacks, safety findings, regulatory delays, and partner decisions (including a partner pausing or returning a program) could all materially affect the stock, which is volatile like most clinical-stage biotech. The most pessimistic published target is $87.00, +0.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Arrowhead Pharmaceuticals do?
+
Arrowhead Pharmaceuticals is a biopharmaceutical company built around RNA interference (RNAi), using its TRiM (Targeted RNAi Molecule) platform to design small interfering RNA (siR
What would have to change for ARWR to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (REDEMPLO (plozasiran) launch and label expansion) stalling in the reported numbers rather than in the narrative, the risk above (arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Arrowhead Pharmaceuticals do?
+
Arrowhead develops RNA interference (RNAi) medicines using small interfering RNA (siRNA) to silence disease-causing genes. Its TRiM platform delivers these drugs to the liver and increasingly to other tissues, targeting cardiometabolic, rare, pulmonary, and muscle diseases.
Is ARWR profitable?
+
Arrowhead reports profits only in quarters with large partner milestone payments and posts operating losses otherwise. As of JULY 2026 its revenue is lumpy and deal-driven rather than coming from steady product sales, so it is not consistently profitable.
What is plozasiran (REDEMPLO)?
+
Plozasiran, marketed as REDEMPLO, is Arrowhead's lead siRNA drug that targets APOC3 to lower triglycerides. It won FDA approval in November 2025 for familial chylomicronemia syndrome (FCS) and has also been approved in China, Canada, Australia, and the EU.
Walnut is informational, not investment advice, and gives no verdict on ARWR. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.